{"id":2866,"date":"2026-08-15T05:18:21","date_gmt":"2026-08-14T23:48:21","guid":{"rendered":"https:\/\/glianomics.com\/blog\/?p=2866"},"modified":"2026-08-15T05:50:53","modified_gmt":"2026-08-15T00:20:53","slug":"semaglutide-naion-rare-risk-serious-symptom","status":"publish","type":"post","link":"https:\/\/glianomics.com\/blog\/semaglutide-naion-rare-risk-serious-symptom\/","title":{"rendered":"Semaglutide and NAION: Rare Risk, Serious Symptom"},"content":{"rendered":"\n

A shop owner in Kochi, two years into semaglutide treatment for type 2 diabetes, woke one morning and reached for his phone out of habit. Covering his left eye to check the time, he noticed the right side of the room had gone dim and grey, like a curtain had dropped over the lower half of what he could see. No pain. No warning. The left eye, when he switched, worked exactly as it always had.<\/p>\n\n\n\n

That pattern – sudden, one-sided, and painless – is called non-arteritic anterior ischemic optic neuropathy, or NAION. It is rare. It is also serious enough that European regulators have now added it directly to semaglutide’s safety information. By the end of this piece, you will know what NAION actually looks like, exactly how rare “rare” means in real numbers, and precisely what to do – and not do – if you notice it.<\/p>\n\n\n\n

What NAION Actually Is<\/h2>\n\n\n\n

NAION happens when blood flow to the optic nerve, where it leaves the back of the eye, is briefly interrupted. The result is sudden, usually painless vision loss or dimming in one eye – often discovered on waking, often affecting the lower half of that eye’s field of view first.[5] It does not build gradually. It is there when you notice it.<\/p>\n\n\n\n

This is a different event from the blurred vision covered in an earlier piece on this site: gradual over days, both eyes evenly affected, and painless. That pattern has a specific mechanism behind it \u2013 shifting blood sugar changes how much sorbitol builds up in the lens (an enzyme called aldose reductase converts glucose to sorbitol), which alters the lens’s osmotic pressure and temporarily shifts your refractive error.[6] It settles on its own as blood sugar stabilizes. NAION is the opposite on every count – sudden, one eye, and it does not resolve by itself. If your blurred vision affects both eyes, and is reversible or variable, the earlier, more common pattern is the likelier explanation; this piece is about the rarer, acute one.<\/p>\n\n\n\n

What the EMA Actually Concluded<\/h2>\n\n\n\n

In 2025, the European Medicines Agency’s safety committee, PRAC, completed a formal review of semaglutide and NAION, examining non-clinical data, clinical trial results, post-marketing reports, and the published literature together.[1] Its conclusion: NAION is a very rare side effect of semaglutide, meaning it may affect up to 1 in 10,000 people taking the medicine.[1]<\/p>\n\n\n\n

The review quantified the signal, too. Large epidemiological studies suggest semaglutide use in adults with type 2 diabetes carries roughly a two-fold increase in NAION risk versus non-use – about one additional case per 10,000 person-years of treatment.[1] Trial data pointed the same direction, with a slightly higher rate on semaglutide than placebo. EMA’s guidance is direct: sudden vision loss or rapidly worsening eyesight during treatment should prompt contacting a doctor without delay, and if NAION is confirmed, treatment is typically stopped – a decision made with your doctor, based on an actual diagnosis, not one to make alone on suspicion.[1]<\/p>\n\n\n\n

What the Underlying Studies Show<\/h2>\n\n\n\n

Three separate research groups arrived at similar conclusions from different data.<\/p>\n\n\n\n

The first signal came from a US neuro-ophthalmology clinic’s retrospective review of patients seen between December 2017 and November 2023.[2] Among patients with type 2 diabetes, those prescribed semaglutide had a NAION hazard ratio of 4.28 (95% CI 1.62-11.29) versus those on other diabetes medications; among patients treated for overweight or obesity, the hazard ratio was 7.64 (95% CI 2.21-26.36).[2] These are the largest estimates of the three studies, and the least generalizable – a specialist referral population already enriched for optic-nerve risk factors, which tends to inflate relative-risk figures.<\/p>\n\n\n\n

A Danish nationwide registry study of all 424,152 people with type 2 diabetes in Denmark, 2018-2024, found a more moderate signal: hazard ratio 2.19 (95% CI 1.54-3.12), incidence roughly 2.3 per 10,000 person-years on semaglutide versus 0.9 off it.[3] A follow-up Danish-Norwegian registry study, comparing new semaglutide users directly against a different diabetes drug class (SGLT-2 inhibitors), found a pooled hazard ratio of 2.81 (95% CI 1.67-4.75) – about 1.41 additional cases per 10,000 person-years – while explicitly concluding “absolute risk remains low.”[4]<\/p>\n\n\n\n

\"fig1<\/figure>\n\n\n\n

Semaglutide and NAION risk – hazard ratio comparison bar chart across four study estimates, with 95% confidence intervals, showing all estimates above 1 but absolute risk remaining low.
All four estimates point toward increased relative risk, but they vary by study design – the two Scandinavian registry studies (general type 2 diabetes populations) show smaller, more consistent effects than the US referral-clinic study (a population already selected for eye problems). Sources: Hathaway JT et al., JAMA Ophthalmol 2024 (PMID 38958939); Grauslund J et al., Int J Retina Vitreous 2024 (PMID 39696569); Simonsen E et al., Diabetes Obes Metab 2025 (PMID 40098249).[2][3][4]<\/em><\/p>\n\n\n\n

Why the Mechanism Isn’t Settled<\/h2>\n\n\n\n

What actually causes NAION in someone on semaglutide is not fully worked out, and it is worth being honest about that rather than presenting a tidy explanation.<\/p>\n\n\n\n

The leading hypothesis involves the optic nerve head’s structure. People with a smaller, more “crowded” optic disc – identifiable on eye imaging – are already known to carry higher baseline NAION risk, independent of any medication.[5] One proposed link to semaglutide is that rapid blood sugar improvement, the same phenomenon that can temporarily worsen existing diabetic retinopathy, may affect blood flow and venous congestion at the nerve head in people who already have this crowded-disc structure.[5] That remains a hypothesis, not an established mechanism.<\/p>\n\n\n\n

It is worth keeping this separate from a different question \u2013 whether GLP-1 medicines as a class raise the overall risk of diabetic retinopathy. A 2025 systematic review and meta-analysis pooling 39 studies found no significant association between GLP-1 receptor agonists and diabetic retinopathy risk overall (pooled relative risk 1.00), though it noted that long-term data remain limited and the evidence is not conclusive either way.[7] That is a broader question about the retina as a whole, distinct from the specific, rare optic-nerve event this piece is about \u2013 the two should not be conflated.<\/p>\n\n\n\n

A 2025 review of the evidence put it plainly: given the retrospective, observational nature of every study so far, causality cannot be inferred from this data.[5] The studies show a consistent statistical association, not proof that semaglutide causes NAION in a given person. A real regulatory risk signal and a genuinely unresolved question about mechanism are both true at once.<\/p>\n\n\n\n

A Caution, Stated Plainly<\/h2>\n\n\n\n

A few things worth being direct about.<\/p>\n\n\n\n

NAION is rare in absolute terms. The increased risk reported across the underlying studies is statistically significant[2][3][4] \u2013 not a chance finding \u2013 but the absolute risk it describes is very low: even the highest relative-risk estimate above still translates to a small number of actual cases, and EMA’s own “very rare” classification sets the bar at up to 1 in 10,000 people on the medicine.[1] This is not a reason to stop your medication out of fear, or to panic if you have been on semaglutide for months or years with no eye symptoms.<\/p>\n\n\n\n

It is, however, a genuine red-flag symptom if it happens. Sudden, usually painless vision loss or dimming in one eye – especially noticed on waking, especially affecting part of your field of view rather than all of it – needs medical or eye care the same day, not a wait-and-watch approach at home. Early evaluation matters for confirming the diagnosis and protecting the unaffected eye, even though NAION itself has no treatment proven to reverse vision already lost.<\/p>\n\n\n\n

Do not stop or change your semaglutide dose on your own if you notice this or any other sudden symptom. Talk to your doctor immediately. They can examine your eye, confirm or rule out NAION, and decide with you whether treatment continues, pauses, or stops – guided by an actual diagnosis, not a checklist read at home.<\/p>\n\n\n\n

More broadly, any new blurred vision \u2013 not just sudden one-eye vision loss \u2013 is worth mentioning to your doctor rather than waiting to see if it resolves on its own. A baseline ophthalmic exam before starting or continuing semaglutide \u2013 covering your current vision, a diabetic retinopathy check, your baseline refractive error, and a look at your optic disc for crowding or other undiagnosed conditions like glaucoma \u2013 is a reasonable, low-burden step. It gives you and your doctor a clearer starting point to work from if anything changes later, and builds confidence either way.<\/p>\n\n\n\n

Questions to Bring to Your Doctor<\/h2>\n\n\n\n
    \n
  1. Do I have any known personal risk factors for NAION – a crowded optic disc, uncontrolled blood pressure, sleep apnea, or a prior episode in either eye?<\/li>\n\n\n\n
  2. Would a baseline ophthalmic exam make sense before I start or continue semaglutide \u2013 checking my current vision, screening for diabetic retinopathy, noting my baseline refractive error, and checking my optic disc and eye pressure for anything undiagnosed, like glaucoma?<\/li>\n\n\n\n
  3. What exactly should sudden one-eye vision loss feel like, and how quickly should I call you if it happens?<\/li>\n\n\n\n
  4. If I notice a sudden vision change, should I go straight to an eye emergency service, a general emergency room, or call you first?<\/li>\n\n\n\n
  5. Does the recent EMA safety update on NAION change anything about my current treatment plan?<\/li>\n<\/ol>\n\n\n\n

    The Bottom Line<\/h2>\n\n\n\n

    NAION is a real, regulator-confirmed risk of semaglutide – and, by every study measuring it, very rare. Both facts matter; neither cancels the other. The mechanism is still being worked out, but the practical guidance is not complicated: know the symptom (sudden, painless, one eye), treat it as same-day urgent, and never make a dosing decision alone based on fear rather than a diagnosis.<\/p>\n\n\n\n

    Tracking your symptoms, any vision changes, and the exact timing against your dose history gives your doctor what they need to sort routine concerns from urgent ones – quickly, without guesswork.<\/p>\n\n\n\n

    This article is for education only and does not replace medical advice. If you notice sudden vision changes in one eye while using semaglutide or any GLP-1 medication, contact your doctor or seek urgent eye care the same day – they can assess your personal risk factors and confirm whether NAION or another cause is responsible.<\/em><\/p>\n\n\n\n

    \n
    \n

    Join the Field Notes<\/h2>

    Metabolic Field Notes tracks the evidence as it develops, without protocol-pushing and without hype. If evidence-aware, translational science is useful to you, join the Field Notes.<\/p><\/div>\n<\/div>\n\n\n\n

    \n
    Email<\/div><\/div>\n
    <\/div>
    <\/div>